Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial
Robert Howard(University College London), Richard Gray(Barnsley Hospital NHS Foundation Trust), Cornelius Katona(University College London), John Sykes, Val Curran, Robert Barber(University of North Texas), Ramin Nilforooshan(University of Surrey), Rosie Bradley, Craig Ritchie(Western General Hospital), Suzanne Reeves(King's College London), Tom Dening(University of Nottingham), Waleed Fawzi(East London NHS Foundation Trust), Martín Knapp(London School of Economics and Political Science), Peter Bentham(Queen Elizabeth Hospital Birmingham), Linda Kelly(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pranathi Ramachandra(Cambridgeshire and Peterborough NHS Foundation Trust), Gill Livingston(North East London NHS Foundation Trust), Ejaz Nazir(Shropshire Community Health NHS Trust), Elizabeth Cort(University College London), Ajay Macharouthu(Crichton Royal Hospital), Andrew Sommerlad(Central and North West London NHS Foundation Trust), Chris Fox(University of California, Irvine), Sabu Oomman(Cheshire West and Chester), Emma Harper(MRC Population Health Research Unit), Vivek Pattan(NHS Forth Valley)
Cited by 66
Related Papers
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
|The Lancet|2024|2.8k
Cost of disorders of the brain in Europe 2010
|European Neuropsychopharmacology|2011|1.7k
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
Plastic waste associated with disease on coral reefs
|Science|2018|844
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
|New England Journal of Medicine|2012|774